Trials / Completed
CompletedNCT06370715
A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India
A 26- Week, Multicenter, Open-Label, Single-Arm, Phase 4 Study to Assess The Safety of Lyumjev in Adult Patients With Type 2 Diabetes Mellitus in India
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 150 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety of insulin lispro-aabc in adult participants with Type 2 diabetes mellitus in India. The study will last about 33 weeks for each participant, including screening (1 week), Lead-in period (4 weeks), treatment period (26 weeks) and follow up period (2 weeks).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Insulin Lispro-aabc | Administered SC |
| DRUG | Insulin Glargine | Administered SC |
Timeline
- Start date
- 2024-04-18
- Primary completion
- 2025-09-02
- Completion
- 2025-09-02
- First posted
- 2024-04-17
- Last updated
- 2025-10-16
Locations
12 sites across 1 country: India
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06370715. Inclusion in this directory is not an endorsement.